Rehmann Capital Advisory Group’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $350K | Sell |
5,577
-39
| -0.7% | -$3.12K | 0.02% | 506 |
|
|
2025
Q4 | $535K | Sell |
5,616
-128
| -2% | -$12.5K | 0.03% | 371 |
|
|
2025
Q3 | $561K | Sell |
5,744
-134
| -2% | -$13.9K | 0.03% | 361 |
|
|
2025
Q2 | $631K | Buy |
5,878
+311
| +6% | +$31.5K | 0.04% | 306 |
|
|
2025
Q1 | $562K | Buy |
5,567
+322
| +6% | +$32.4K | 0.04% | 333 |
|
|
2024
Q4 | $468K | Buy |
5,245
+339
| +7% | +$29.8K | 0.03% | 368 |
|
|
2024
Q3 | $415K | Sell |
4,906
-7
| -0.1% | -$552 | 0.03% | 381 |
|
|
2024
Q2 | $378K | Buy |
4,913
+120
| +3% | +$8.78K | 0.03% | 393 |
|
|
2024
Q1 | $328K | Sell |
4,793
-256
| -5% | -$16.5K | 0.02% | 427 |
|
|
2023
Q4 | $292K | Buy |
5,049
+58
| +1% | +$3.1K | 0.02% | 440 |
|
|
2023
Q3 | $264K | Sell |
4,991
-165
| -3% | -$8.65K | 0.02% | 428 |
|
|
2023
Q2 | $279K | Buy |
5,156
+129
| +3% | +$6.74K | 0.03% | 441 |
|
|
2023
Q1 | $252K | Buy |
5,027
+379
| +8% | +$17.9K | 0.02% | 462 |
|
|
2022
Q4 | $215K | Buy |
+4,648
| New | +$201K | 0.02% | 504 |
|
|
2020
Q3 | – | Sell |
-9,829
| Closed | -$345K | – | 428 |
|
|
2020
Q2 | $345K | Buy |
9,829
+2,190
| +29% | +$78.9K | 0.05% | 300 |
|
|
2020
Q1 | $249K | Buy |
+7,639
| New | +$298K | 0.04% | 327 |
|
|
2019
Q3 | $415K | Sell |
10,194
-3,582
| -26% | -$152K | 0.05% | 188 |
|
|
2019
Q2 | $592K | Sell |
13,776
-37
| -0.3% | -$1.42K | 0.07% | 217 |
|
|
2019
Q1 | $530K | Buy |
13,813
+179
| +1% | +$6.84K | 0.07% | 207 |
|
|
2018
Q4 | $482K | Buy |
13,634
+665
| +5% | +$24.1K | 0.07% | 139 |
|
|
2018
Q3 | $499K | Buy |
12,969
+995
| +8% | +$34.8K | 0.07% | 212 |
|
|
2018
Q2 | $392K | Sell |
11,974
-2,206
| -16% | -$66.5K | 0.06% | 246 |
|
|
2018
Q1 | $387K | Buy |
14,180
+2,853
| +25% | +$77.5K | 0.06% | 232 |
|
|
2017
Q4 | $281K | Sell |
11,327
-804
| -7% | -$22.2K | 0.05% | 293 |
|
|
2017
Q3 | $354K | Buy |
12,131
+3,432
| +39% | +$94.8K | 0.06% | 236 |
|
|
2017
Q2 | $241K | Buy |
+8,699
| New | +$231K | 0.05% | 304 |
|
|
2016
Q4 | – | Sell |
-13,320
| Closed | -$317K | – | 385 |
|
|
2016
Q3 | $317K | Buy |
13,320
+1,824
| +16% | +$43.5K | 0.06% | 248 |
|
|
2016
Q2 | $269K | Buy |
11,496
+211
| +2% | +$4.57K | 0.05% | 277 |
|
|
2016
Q1 | $212K | Sell |
11,285
-4,171
| -27% | -$73.3K | 0.04% | 319 |
|
|
2015
Q4 | $285K | Sell |
15,456
-55
| -0.4% | -$986 | 0.06% | 238 |
|
|
2015
Q3 | $255K | Sell |
15,511
-1,171
| -7% | -$20K | 0.06% | 254 |
|
|
2015
Q2 | $295K | Sell |
16,682
-694
| -4% | -$12.4K | 0.07% | 226 |
|
|
2015
Q1 | $308K | Buy |
17,376
+618
| +4% | +$9.77K | 0.07% | 232 |
|
|
2014
Q4 | $222K | Buy |
+16,758
| New | +$214K | 0.05% | 296 |
|
Other funds holding BSX
VCM
VPM
Rehmann Capital Advisory Group's BSX Position: Q1 2026 in Review
Rehmann Capital Advisory Group reduced its Boston Scientific (BSX) stake by 0.69% in Q1 2026, selling an estimated $3.12K and leaving 5,577 shares worth $350K. The position accounts for 0.02% of the portfolio, ranked #506.
Rehmann Capital Advisory Group first reported a position in BSX in Q4 2014 and has held it in 34 quarters since. The position peaked at $631K in Q2 2025. 1,666 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- Rehmann Capital Advisory Group held 5,577 shares of Boston Scientific worth $350K as of Q1 2026.
- Rehmann Capital Advisory Group sold 39 Boston Scientific shares in Q1 2026, an estimated $3.12K.
- Boston Scientific made up 0.02% of Rehmann Capital Advisory Group's portfolio in Q1 2026, its #506 holding.
- Rehmann Capital Advisory Group first reported a position in Boston Scientific in Q4 2014 and has held it in 34 quarters since.
- Rehmann Capital Advisory Group's Boston Scientific position peaked at $631K in Q2 2025.
- 1,666 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on Rehmann Capital Advisory Group's 13F filing for Q1 2026, filed 15 May 2026.